Virogen, Inc. Receives Manufacturing License Opening Door to Sales in Worldwide Market

MINNEAPOLIS, MN–(EMWNews – August 19, 2008) – Virogen, Inc. (PINKSHEETS: VRGI), the

developer and patent holder of a revolutionary vaccine to combat Newcastle

disease, a deadly disease that kills chickens worldwide, announced that on

July 19, 2008 a manufacturing license was issued for its Innovo Immune

Newcastle Vaccine by the Government of Romania, a European Economic

Community member country. This certification meets the European Union

standard which is recognized by virtually every country in the world.

Licensing Within European Union

Manufacturing within a European Union (EU) member country has allowed

access to the EU market and paved the way for the company to fast track

registration of the vaccine in countries worldwide in the shortest possible

time. The license issued on July 19, 2008 has opened the door for Virogen

to manufacture and export its vaccine worldwide and pursue registrations in

all of its major markets.

Statement by Paul Hogan, CEO

Paul Hogan, CEO of Virogen, Inc., notes, “Every production bird in the

world is required to be vaccinated, and since Virogen’s vaccine is

breakthrough technology and the most effective Innovo patent-protected

product on the market, the company anticipates it will capture this

exclusive market for several years. With approximately 45 billion birds

being produced annually outside of the United States, and consumption

growing by close to 30% per annum and expected to increase further, one can

anticipate the revenue opportunity for this vaccine is in the tens of

millions over the product life cycle.”

The Company

Virogen is a Minnesota-based Corporation formed solely to conduct research,

and develop vaccines for the veterinary industry worldwide. The company’s

flagship product is its Innovo Newcastle Vaccine.

Forward-Looking Statements:

This press release contains statements, which may constitute

“forward-looking statements” within the meaning of the Securities Act of

1933 and the Securities Exchange Act of 1934, as amended by the Private

Securities Litigation Reform Act of 1995. Those statements include

statements regarding the intent, belief or current expectations of Virogen,

Inc. and members of its management as well as the assumptions on which such

statements are based. Prospective investors are cautioned that any such

forward-looking statements are not guarantees of future performance and

involve risks and uncertainties, and that actual results may differ

materially from those contemplated by such forward-looking statements. The

Company undertakes no obligation to update or revise forward-looking

statements to reflect changed assumptions, the occurrence of unanticipated

events or changes to future operating results.

Investors and potential investors are invited to call either Guy Vinci, VUI

Consulting at (386) 218-5929 or Paul Hogan, CEO, Virogen, Inc. at

(415) 367-4058 to request a copy of the company’s complete business plan.